<DOC>
	<DOCNO>NCT00112567</DOCNO>
	<brief_summary>RATIONALE : Chemotherapy , fludarabine thiotepa , radiation therapy may destroy cancerous blood-forming cell ( stem cell ) blood bone marrow . Giving healthy stem cell donor whose blood closely resemble patient 's blood help patient 's bone marrow make new stem cell become red blood cell , white blood cell , platelet . PURPOSE : This phase I/II trial study side effect total-body irradiation , fludarabine , thiotepa see well work treat young patient undergo donor stem cell transplant hematologic cancer .</brief_summary>
	<brief_title>Total-Body Irradiation , Thiotepa , Fludarabine Treating Young Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety condition regimen without anti-thymocyte globulin comprise total body irradiation , thiotepa , fludarabine follow CD34-positive-selected haploidentical allogeneic peripheral blood stem cell transplantation young patient life-threatening hematologic malignancy . Secondary - Determine risk severe graft-vs-host disease patient treat regimen . - Determine kinetics immune reconstitution patient treat regimen . - Determine risk life-threatening infection patient treat regimen . OUTLINE : - Conditioning regimen : Patients 7 year age undergo total body irradiation twice daily day -9 -7 . Patients 7 year age undergo total body irradiation day -7 . All patient receive fludarabine IV daily day -6 -2 thiotepa IV 2 hour twice day -5 . - CD34-positive ( CD34+ ) -selected haploidentical allogeneic peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo CD34+-selected allogeneic PBSCT day 0 2 . Patients acute lymphoblastic leukemia CNS disease also receive methotrexate intrathecally twice transplantation 4 time day 35 post-transplantation . Male patient lymphoid malignancy undergo additional radiotherapy testis . After completion study treatment , patient follow least 100 day , 1 year , periodically thereafter . PROJECTED ACCRUAL : A total 20 patient ( 10 patient ≤ 7 year age 10 patient &gt; 7 year age ) accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis lifethreatening hematologic malignancy , include follow : Acute leukemia advance beyond first remission Acute leukemia first remission* highrisk prognostic feature , include follow : Philadelphia chromosomepositive acute lymphoblastic leukemia ( ALL ) ALL acute myeloid leukemia ( AML ) 11q23 chromosomal abnormality Hypodiploid ALL Failed achieve first remission within 1 month induction therapy Secondary AML Myelodysplastic syndromes International Prognostic Index score &gt; 1 Chronic myelogenous leukemia accelerate blast phase NOTE : *Must approve PCC Haploidentical family donor available No suitable HLAmatched relate unrelated donor available No related donor mismatch single HLAA , B , C , DRB1 , DQB1 antigen available PATIENT CHARACTERISTICS : Age Under 21 Performance status Not specify Life expectancy At least 6 month Hematopoietic Not specify Hepatic SGPT SGOT &lt; 2 time upper limit normal ( ULN ) * Bilirubin &lt; 2 time ULN* NOTE : *Unless due malignancy Renal Not specify Cardiovascular Ejection fraction ≥ 45 % Pulmonary DLCO ≥ 60 % predict Other Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy No second bone marrow transplantation , first regimen contain total body irradiation No concurrent growth factor day 21 posttransplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Biologic therapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>